Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | PYGM | P11217 | 1/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.49 |
| ▸ | VDR | P11473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775026 | 1.00 | KDM4E (0.77) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL28560551 | 0.92 | KDM4E (0.63) | KDM4EPOLBHTTKMT2ACTNNB1 | |
| SCHEMBL13851461 | 0.90 | HTT (0.67) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL28264707 | 0.90 | KDM4E (0.61) | KDM4EPOLBHTTKMT2ACTNNB1 | |
| SCHEMBL13682882 | 0.89 | POLB (0.65) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL5660471 | 0.86 | KDM4E (0.62) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL13687396 | 0.86 | CTNNB1 (0.68) | KDM4EPOLBMEN1KMT2AMTNR1B | |
| SCHEMBL2863787 | 0.85 | HTT (0.69) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL7919800 | 0.84 | KDM4E (0.64) | KDM4EPOLBHTTMEN1KMT2A | |
| SCHEMBL2657444 | 0.84 | KDM4E (0.56) | KDM4EPOLBHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117164517-A | Phenoxybenzamide derivative containing substituted pyrazole, preparation method and application thereof | 西北农林科技大学 | 2023-12-05 | — | — | CN | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-10933072-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2009111447-A2 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | SENOMYX, INC. | 2009-09-03 | — | — | US | disclosed |
| US-20080206158-A1 | Benzoic Acid Ester Compounds, Compositions, Uses and Methods Related Thereto | FERRER INTERNACIONAL, S.A. (ES) | 2008-08-28 | — | — | US | disclosed |
| EP-1868984-A2 | BENZOIC ACID ESTER COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-12-26 | — | — | EP | disclosed |
| EP-1707558-A1 | Benzoic acid ester compounds, compositions, uses and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2006-10-04 | — | — | EP | disclosed |
| WO-2006100225-A2 | BENZOIC ACID ESTER COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-28 | — | — | WO | disclosed |
| EP-0442748-B1 | Improvements in and relating to leukotriene antagonists | LILLY CO ELI (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0442748-A1 | Improvements in and relating to leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1991-08-21 | — | — | EP | disclosed |
| US-4996230-A | Antiallergens, antiinflammatory agent | ELI LILLY AND COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| US-4267344-A | 3-PENTA/ALKOXY/BENZYL-; -XANTHYL-, -THIOXANTHYL-, OR -SELENOXANTHYLOXAZOLIDINE-2,5-DIONES | PROTEINKEMISK INSTITUT. TILKNYTTET AKADEMIET FOR DE TEKNISKE VIDENSKABER (DK) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | KDM4E 2023/4885POLB 2959/4885HTT 1476/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | KDM4E 1290/4885POLB 2216/4885HTT 4016/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | KDM4E 2023/4885POLB 2959/4885HTT 1476/4885 |
| US-10933072-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | KDM4E 1290/4885POLB 2216/4885HTT 4016/4885 |
| US-20090220662-A1 | ISOSORBIDE DERIVATIVES AND THEIR USE AS FLAVOR MODIFIERS, TASTANTS, AND TASTE ENHANCERS | TAS2R10, TAS2R41, TAS2R30 | KDM4E 2993/4885POLB 3874/4885HTT 2197/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | KDM4E 270/4885POLB 3484/4885HTT 1960/4885 |
| US-20080206158-A1 | Benzoic Acid Ester Compounds, Compositions, Uses and Methods Related Thereto | VKORC1, CYP51A1, CYP19A1 | KDM4E 1575/4885POLB 847/4885HTT 1204/4885 |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | KDM4E 1290/4885POLB 2216/4885HTT 4016/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | KDM4E 1290/4885POLB 2216/4885HTT 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.